Avtor/Urednik		Medvešček, Marko
Naslov		Cardiac and renal protection in type 2 diabetes in view of recent relevant clinical trials: implications for clinical guidelines
Tip		članek
Vir		In: Štiblar-Martinčič D, Petrovič D, editors. Cardiovascular diseases. Proceedings of the 32nd memorial meeting devoted to professor Janez Plečnik, International symposium in memory of professor Rene Favaloro; 2001 Dec 6-8; Ljubljana. Ljubljana: Medical faculty,
Leto izdaje		2001
Obseg		str. 329-35
Jezik		eng
Abstrakt		Cardiovascular diseases are the main source of higher death rate in type 2 diabetics. Mortality from cardiovascular causes is much higher in patients with evidence of diabetic nephropathy. It is necessary to treat patients agressively to prevent both cardiovascular disease, in particular coronary heart disease (CHD), and diabetic nephropathy. The high risk for CHD introduces the secondary prevention procedure for CHD in people with type 2 diabetes without CHD. Surprisingly, there is a lack of CHD prevention studies in the type 2 diabetes pipulation. The secondary prevetion studies were mainly post-hoc subgroup analysis studies, which implicate certain limitations, but the results were at least as good as in nondiabetic population. The first CHD primary prevetion study with HMGCoA inhibitor simvastatin (Heart Protection Study) is to be published shortly. Diabetic nephropathy can be prevented through appropriate strategy of primary, secondary, and tertiary prevention. New studies have recently been published, demonstrating beneficial effects of selective angiotensin AII receptor antagonists in attenuating progression of the renal disease. The most convincing results were shown with losartan which reduced the end-stage-renal-failure by 28%, thus delaying it for approximately 2 years.
Deskriptorji		DIABETES MELLITUS, NON-INSULIN-DEPENDENT CORONARY DISEASE DIABETIC NEPHROPATHIES ANGIOTENSIN-CONVERTING ENZYME INHIBITORS HYDROXYMETHYLGLUTARYL COA REDUCTASES KIDNEY FAILURE, CHRONIC